Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H32O2 |
Molecular Weight | 340.499 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C=C(C)C4=CC(=O)CC[C@]34C
InChI
InChIKey=HCFSGRMEEXUOSS-JXEXPEPMSA-N
InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4288903Curator's Comment: description was created based on several sources, including http://www.cngof.asso.fr/d_livres/1996_GO_157_laurent.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4288903
Curator's Comment: description was created based on several sources, including http://www.cngof.asso.fr/d_livres/1996_GO_157_laurent.pdf
Medrogestone is a progesterone derivative used for the treatment of progesterone deficiency, especially those observed in the premenopausal period, haemorrhages and menorrhagia of fibroids, endometriosis, menstrual cycle disorders, etc. The drug acts by binding and activating progesterone receptors. In Europe, medrogestone is available under the name Colprone, however it is no longer marketed in the USA, Germany and Austria.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4288903 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | COLPRONE Approved UseDisorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea. |
|||
Primary | COLPRONE Approved UseDisorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea. |
|||
Palliative | COLPRONE Approved UseDisorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea. |
|||
Primary | COLPRONE Approved UseDisorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea. |
|||
Primary | COLPRONE Approved UseDisorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea. |
PubMed
Title | Date | PubMed |
---|---|---|
Biological effects of progestins in breast cancer. | 2001 Dec |
|
Cyclic progestin therapy for the management of mastopathy and mastodynia. | 2001 Dec |
|
Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control. | 2001 Feb |
|
The selective estrogen enzyme modulator (SEEM) in breast cancer. | 2001 Jan-Mar |
|
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. | 2001 May |
|
Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. | 2002 Dec 10 |
|
Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen. | 2002 Feb 26 |
|
Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. | 2002 Feb 26 |
|
[Tibolone]. | 2002 Sep 7 |
|
Differential effects of progestins on breast tissue enzymes. | 2003 Dec 10 |
|
Androgens and antiandrogens. | 2003 Nov |
|
The selective estrogen enzyme modulators in breast cancer: a review. | 2004 Jun 7 |
|
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. | 2005 Feb |
|
Influence of different HRT regimens on mammographic density. | 2005 Feb 14 |
|
Age-related cognitive decline in the menopause: effects of hormone replacement therapy on cognitive event-related potentials. | 2005 Jul 16 |
|
Effects of hormone replacement therapy on the main fatty acids of serum and phospholipids of postmenopausal women. | 2005 Nov-Dec |
|
Breast cancer risk associated with different HRT formulations: a register-based case-control study. | 2006 Sep 12 |
|
Oral progestagens before menopause and breast cancer risk. | 2007 Mar 12 |
|
Colon cancer risk and different HRT formulations: a case-control study. | 2007 May 8 |
|
Progestins and breast cancer. | 2007 Oct |
|
Free synthetic and natural estrogen hormones in influent and effluent of three municipal wastewater treatment plants. | 2007 Sep |
|
Correlation of estrogen sulfotransferase activity and proliferation in normal and carcinomatous human breast. A hypothesis. | 2007 Sep-Oct |
|
Progestins in the menopause in healthy women and breast cancer patients. | 2009 Apr 20 |
|
Breast cancer and steroid metabolizing enzymes: the role of progestogens. | 2009 Dec |
|
Estrogen sulfotransferases in breast and endometrial cancers. | 2009 Feb |
|
Presence of steroid hormones and antibiotics in surface water of agricultural, suburban and mixed-use areas. | 2009 Jul |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10215037
T-47D cells were incubated with medrogestone for 24h and the drug inhibited 17beta-hydroxysteroid dehydrogenase activity in a dose-dependent manner by 39% and 80% at 5 x 10(-8) M and 5 x 10(-5) M.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G03DB03
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
||
|
NCI_THESAURUS |
C776
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
||
|
WHO-VATC |
QG03FB07
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
||
|
WHO-ATC |
G03FB07
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
||
|
WHO-VATC |
QG03DB03
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB09124
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
6690
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | RxNorm | ||
|
Medrogestone
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
977-79-7
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
D008524
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
100000091988
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
1852
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
m7132
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2106825
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
9949848
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
C90970
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
DTXSID70878637
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
1657
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
213-555-0
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
123018
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
SUB08696MIG
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY | |||
|
077DN93G5B
Created by
admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY